Antiviral oligonucleotides targeting viral families

• US 20050153912A1
• Filed: 09/12/2003
• Published: 07/14/2005
• Est. Priority Date: 09/13/2002
• Status: Abandoned Application

• Current Assignee: Replicor Inc.
• Original Assignee: Replicor Inc.
• Inventors: Juteau, Jean-Marc, Vaillant, Andrew
• Application Number:
  US10/661,402
• Publication Number:
  US 20050153912A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/11 DNA or RNA fragments; Modified forms thereof DNA or RNA not used in recombinant technology, C07H21/00; Non-coding nucleic acids having a biological activity
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/3125 Methylphosphonates
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/351 Conjugate
• CPC Class Codes: C12N 2310/3521 Methyl
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.

Claims

1. A method for the prophylaxis or treatment of a viral infection in a subject, comprising

administering to a subject in need of such treatment a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide at least 10 nucleotides in length, wherein the anti-viral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action, and wherein the virus is different from HIV-1, HIV-2, HSV-1, HSV-2, CMV, RSV, parainfluenza virus, and HBV.

2. The method of claim 1, wherein said subject is a human.

3. The method of claim 1, wherein said virus is a retroviridae.

4. The method of claim 1, wherein said virus is a herpesviridae.

5. The method of claim 1, wherein said virus is a hepadnaviridae.

6. The method of claim 1, wherein said virus is a paramyxoviridae.

7. The method of claim 1, wherein said virus is a parvoviridae.

8. The method of claim 1, wherein said virus is a poxviridae.

9. The method of claim 1, wherein said virus is a papillomaviridae.

10. The method of claim 1, wherein said virus is an adenoviridae.

11. The method of claim 1, wherein said virus is a bunyaviridae.

12. The method of claim 1, wherein said virus is a picornaviridae.

13. The method of claim 1, wherein said virus is a flaviviridae.

14. The method of claim 1, wherein said virus is a filoviridae.

15. The method of claim 1, wherein said virus is an orthomyxoviridae.

16. The method of claim 1, wherein said virus is a togaviridae.

17. The method of claim 1, wherein said virus is a coronaviridae.

18. The method of claim 1, wherein said virus is a reoviridae.

19. The method of claim 1, wherein said virus is a rhabdoviridae.

20. The method of claim 1, wherein said virus is an arenaviridae.

21. The method of claim 1, wherein said virus is a calciviridae.

33. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein said at least one antiviral oligonucleotide comprises at least one antiviral randomer oligonucleotide.

34. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein said oligonucleotide is not complementary to any portion of the genomic sequence of said target virus.

35. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein said formulation has an IC₅₀ for said target virus of 0.10 μ

M or less.

36. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein said oligonucleotide is at least 40 nucleotides in length.

37. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein each said oligonucleotide comprises at least one modification to its chemical structure.

38. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein each said oligonucleotide comprises at least one phosphorothioated linkage.

39. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein each said oligonucleotide comprises at least one phosphorothioated linkage and is in a formulation comprising a delivery system.

40. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein each said oligonucleotide comprises at least one 2′

-modification to the ribose moiety.

41. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein each said oligonucleotide comprises at least one methylphosphonate linkage.

42. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein each said oligonucleotide comprises at least one phosphorodithioated linkage.

43. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein each said oligonucleotide comprises at least one phosphorodithioated linkage and is in a formulation comprising a delivery system.

44. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein said oligonucleotide is a concatemer consisting of two or more oligonucleotide sequences joined by a linker.

45. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein said oligonucleotide is linked or conjugated at one or more nucleotide residues, to a molecule modifying the characteristics of the oligonucleotide to obtain one or more characteristics selected from the group consisting of higher stability, lower serum interaction, higher cellular uptake, higher viral protein interaction, an improved ability to be formulated for delivery, a detectable signal, higher antiviral activity, better pharmacokinetic properties, specific tissue distribution, lower toxicity.

46. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein said oligonucleotide is double stranded.

47. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein said oligonucleotide binds to one or more viral components.

48. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, wherein at least a portion of the sequence of said oligonucleotide is derived from a viral genome.

49. The method, pharmaceutical composition, or kit of claim 1, 22, or 31, comprising a mixture of at least two different antiviral oligonucleotides.

50. The method, pharmaceutical composition, or kit of claim 49, wherein a plurality of said different oligonucleotides are at least 10 nucleotides in length.

51. The method, pharmaceutical composition, or kit of claim 49, wherein a plurality of said different oligonucleotides are at least 40 nucleotides in length.

22. An antiviral pharmaceutical composition comprising

a therapeutically effective amount of at least one pharmacologically acceptable, antiviral oligonucleotide at least 10 nucleotides in length, wherein said composition is approved for use in humans against a target virus, and the antiviral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action, and said target virus is different from HIV-1, HIV-2, HSV-1, HSV-2, CMV, RSV, parainfluenza virus, and HBV;

and

a pharmaceutically acceptable carrier.

23. The antiviral pharmaceutical composition of claim 22, adapted for delivery by oral ingestion.

24. The antiviral pharmaceutical composition of claim 22, adapted for delivery enterally.

25. The antiviral pharmaceutical composition of claim 22, adapted for delivery by injection.

26. The antiviral pharmaceutical composition of claim 22, adapted for delivery by inhalation.

27. The antiviral pharmaceutical composition of claim 22, adapted for delivery topically.

28. The antiviral pharmaceutical composition of claim 22, wherein said composition further comprises a delivery system.

29. The antiviral pharmaceutical composition of claim 22, wherein said composition further comprises a liposomal formulation.

30. The antiviral pharmaceutical composition of claim 22, wherein said composition further comprises at least one other antiviral drug in combination.

31. A kit comprising at least one anti-viral oligonucleotide or anti-viral oligonucleotide formulation in a labeled package, wherein said oligonucleotide is at least 10 nucleotides in length, the anti-viral activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action, and the label on said package indicates that said anti-viral oligonucleotide can be used against a target virus different from HIV-1, HIV-2, HSV-1, HSV-2, CMV, RSV, parainfluenza virus, and HBV.

32. The kit of claim 31, wherein said kit is approved by a regulatory agency for use in humans.

52. A method for selecting an antiviral oligonucleotide for use as an anti-viral agent against a target virus different from HIV-1, HIV-2, HSV-1, HSV-2, CMV, RSV, parainfluenza virus, and HBV, comprising

synthesizing a plurality of different oligonucleotides, wherein at least one of said different oligonucleotides is at least 10 nucleotides in length;

testing said oligonucleotides for activity in inhibiting the ability of said target virus to produce infectious virions,

selecting a said oligonucleotide having a pharmaceutically acceptable level of activity for use as an anti-viral agent.

53. The method of claim 52, wherein said different oligonucleotides comprise randomers of different lengths.

54. The method of claim 52, wherein said different oligonucleotides comprise a set of oligonucleotides of different length, each oligonucleotide in said set comprising the sequence of the shortest oligonucleotide in said set.

55. The method of claim 52, wherein said different oligonucleotides comprise a plurality of oligonucleotides comprising a randomer segment at least 6 nucleotides in length.

56. The method of claim 52, wherein said different oligonucleotides are not complementary to any mRNA sequence of said target virus.

57. A method for the prophylaxis or treatment of a viral infection in a subject, comprising

administering to a subject in need of such treatment a therapeutically effective amount of at least one pharmacologically acceptable oligonucleotide randomer at least 10 nucleotides in length, wherein the anti-viral activity of said randomer occurs principally by a non-sequence complementary mode of action, wherein the virus is different from HIV-1, HIV-2, HSV-1, HSV-2, CMV, RSV, parainfluenza virus, and HBV.